J&J Shares Slip as Investors Assess Loss From Talc Legal Saga

The transcript discusses a $4.7 billion verdict against Johnson & Johnson due to claims that their talc products caused ovarian cancer. Despite the verdict, the company's financial health appears strong, with rising free cash flow and diversified revenue streams, particularly from pharmaceuticals. The consumer health division, affected by the lawsuit, now constitutes a smaller portion of total revenue. Analysts believe the company can withstand the financial impact, with many claims likely to be appealed or reduced.

What is the significance of the $4.7 billion verdict in relation to the company's financial health?

What percentage of the company's revenue does the Consumer Health division currently represent?